PURPOSE: To investigate long-term effects after intravitreal inhibition of @entity7 in nonproliferative macular @entity8721 type 2. METHODS: Nine @entity1 with macular @entity8721 type 2 treated with 12 monthly intravitreal ranibizumab injections in 1 eye were investigated again after a mean follow-up of 6.0    0.4 years. Functional assessment included best-corrected visual acuity and microperimetry testing. Morphologic investigations included optical coherence tomography imaging and @entity941 angiography. RESULTS: Mean visual acuity at baseline was similar in treated and control eyes (both 20/50; range: 20/32-20/125 in the treated eyes and 20/25-20/100 in the untreated eyes). None of the eyes had a neovascular membrane or a paracentral @entity1019 . At the last follow-up, more eyes of the treatment group had lost 2 or more lines on best-corrected visual acuity testing (4 vs. 1) and more eyes had developed an absolute paracentral @entity1019 (7 vs. 2). A secondary neovascular membrane had formed in four of the treated and in none of the untreated eyes. CONCLUSION: @entity7 inhibition with monthly dosing over 1 year had no beneficial effect 5 years after cessation of therapy. The worse outcome in the treated eyes may be due to selection bias, small sample size, or a potential adverse effect of @entity7 inhibition in a degenerative, primarily nonvascular disease as macular @entity8721 type 2.

POOR LONG-TERM OUTCOME OF ANTI- XXXX THERAPY IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8721 :: ('MESH:D013684', 'Disease') :: ['telangiectasia'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'Vascular endothelial growth factor'] @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein'] @entity1019 :: ('MESH:D012607', 'Disease') :: ['scotoma']
@entity7 :: (7422,Gene) :: ['VASCULAR ENDOTHELIAL GROWTH FACTOR']
